INSM Form 4: William Lewis Exercises 6,865 Options and Executes 10b5-1 Sales
Rhea-AI Filing Summary
Insmed Inc. insider transactions by Chair and CEO William Lewis show option exercises and multiple stock sales executed under a 10b5-1 plan on 08/18/2025. The filing reports the exercise of 6,865 stock options at an exercise price of $10.85 and the acquisition of 6,865 common shares via that exercise. On the same date the reporting person sold a total of 6,865 common shares in separate sell transactions: 2,968 shares at a weighted average price of $127.59, 2,481 shares at $128.76, and 1,416 shares at $129.47. After these transactions the reporting person beneficially owns 303,911 shares indirectly and 50,500 shares indirectly via two trusts.
Positive
- Transactions executed under a documented 10b5-1 plan, indicating pre-planned and rule-compliant insider sales.
- Options exercised at $10.85 converting to 6,865 shares, illustrating intrinsic value capture versus exercise price.
Negative
- Insider sold 6,865 shares on 08/18/2025, reducing holdings via three sell blocks (2,968; 2,481; 1,416 shares).
- Reported sales at high market prices may be perceived as insider monetization rather than vote of confidence in near-term upside.
Insights
TL;DR: Option exercise followed by plan-led share sales is routine insider liquidity, disclosed under a pre-existing 10b5-1 plan.
The Form 4 indicates the reporting person adopted a 10b5-1 trading plan on September 12, 2024, and executed transactions on August 18, 2025 pursuant to that plan. The disclosure shows option exercises converting to 6,865 shares and contemporaneous open-market sales of the same aggregate amount across three sale blocks at weighted average prices between $127.59 and $129.47. The filing includes clear pricing ranges and an undertaking to provide per-price breakdowns on request, which supports compliance and transparency. Impact is procedural rather than operational.
TL;DR: Insider monetized equity via exercised options and market sales; remaining indirect holdings remain sizeable.
The report shows an exercise price of $10.85 for 6,865 options that became exercisable and were exercised on 08/18/2025. Proceeds were partially realized by selling those shares in three blocks totaling 6,865 shares at weighted average sale prices of $127.59, $128.76, and $129.47. Post-transactions beneficial ownership is reported as 303,911 shares (indirect) plus 50,500 shares (indirect by another trust). For investors, this is a liquidity event by an insider rather than new information about company performance.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 6,865 | $0.00 | -- |
| Exercise | Common Stock | 6,865 | $10.85 | $74K |
| Sale | Common Stock | 2,968 | $127.59 | $379K |
| Sale | Common Stock | 2,481 | $128.76 | $319K |
| Sale | Common Stock | 1,416 | $129.47 | $183K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 2,968 shares sold at prices ranging from $127.20 to $128.16 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 2,481 shares sold at prices ranging from $128.26 to $129.21 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 1,416 shares sold at prices ranging from $129.26 to $129.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.
